New contrast agent shows promise for brain tumor MRI scans
NCT ID NCT06057168
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 3 trial tested whether Elucirem (gadopiclenol) provides better MRI images of brain gliomas compared to the standard contrast agent Dotarem. 138 adults with primary or recurrent brain tumors received one of the two agents during DSC-MRI perfusion scans. The main goal was to compare the quality of blood flow maps, rated as poor, fair, good, or excellent by independent readers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Elucirem (gadopiclenol)
What this could lead to
If successful, Elucirem could become a better contrast agent for MRI scans of brain tumors, helping doctors see tumor blood flow more clearly.
What could go wrong
This is a completed Phase 3 trial, but it only compares image quality, not patient outcomes. The new agent may not be significantly better than the current standard.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN TUMOR, RECURRENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Debreceni Egyetem
Debrecen, Hungary
-
IRCCS C.Mondino, Istituto Neurologico Nazionale, Fondazione
Pavia, Italy
-
Independent Public Teaching Hospital no 1 Department of Interventional Radiology and Diagnostic Imaging
Lublin, Poland
-
Országos Idegtudományi Intézet - Neuroonkológiai és Intracraniá
Budapest, Hungary
-
Ospedale Papa Giovanni XXIII
Bergamo, Italy
-
Ospedale San Raffaele- Neuroradiologia
Milan, Italy
-
Pecsi Tudomanyegyetem Klinikai Kozpont
Pécs, Hungary
-
Policlinico Universitario Agostino Gemelli
Roma, Italy
-
Semmelweis Egyetem - Neurologiai Klinika
Budapest, Hungary
-
Szpital Specjalistyczny im.L.Rydygiera
Krakow, Poland
-
Uniwersyteckie Centrum Kliniczne w Gdansku
Gdansk, Poland